Latest Advisory

Schedule of FDA Seminars in Visayas Cluster

Please be advised of the upcoming FDA Seminars for Visayas Stakeholders wherein the venue will be in Cebu City

Seminar Title  Seminar Code  Date 
QPIRA for Center for Cosmetic Regulation and Research (Cosmetics) QCCRR (VIS) 28-29 June 2018
13 ASEAN Modules and GMP for Cosmetic Manufacturers and Traders  ASEAN-GMp-CMT (VIS)  10-11 July 2018 
QPIRA for Center for Food Regulation and Research   QCFRR-VC  12-13 July 2018 
QPIRA for Center for Cosmetic Regulation and Research (Household and Urban Hazardous Substances)  QCCRR-HUHP (VIS)  16-17 Oct 2018 

For more information, please refer to FDA Circular No. 2018-005 entitled "Training Courses/Seminars and Schedule of Fees for the training Offered by the Food and Drug Administration (FDA) Academy - Policy Planning Services (PPS) for Calendar Year 2018". For inquiries on this activity and other concerns, please call the FDA Academy at telephone number (02) 877 0259 or email at This email address is being protected from spambots. You need JavaScript enabled to view it.. For the course registration process, please visit the following websites: and


Postponement of CFRR QPIRA Seminar for North Luzon Cluster (QCFRR-NLC) on 7-8 June 2018

Please be advised that the CFRR QPIRA Seminar for North Luzon Cluster stakeholders (Course Code: QCFRR-NLC) scheduled in La Union province on 7-8 June 2018 shall be postponed until further notice due to very low number of confirmed participants for the seminar.

For inquiries on this activity and other concerns, please call the FDA Academy at telephone number (02) 877 0259


The CCRR 13 ASEAN Cosmetic GMP Modules for Cosmetics Manufacturers and Traders (ASEAN-GMP-CMT) Seminar on 24-25 May 2018 shall be RESCHEDULE to 30-31 May 2018.

All course registrant who received Course Assessment Slip but have yet to receive the confirmation Slip are advised to come on the seminar venue on the scheduled dates of seminar with the following documents:

  1. Course assessment slip
  2. Proof of payment
  3. Original notarized affidavit of undertaking

our sincere apologize for the inconvenience on this change in seminar schedule. for inquiries and other concerns, please call the FDA Academy at telephone number (02) 877 0259.

Download this file (ANNOUNCEMENT.pdf)ANNOUNCEMENT.pdf
Food and Drug Administration (FDA) Director-General Nela Charade G. Puno last week called on women to have regular breast examinations, saying “early cancer detection can save your lives”.

Puno made the remarks as she announced that her doctors have agreed to let her resume her regular work routine after a brief rest following her breast surgery. This came after she was diagnosed with breast cancer early this year.

According to Puno, her successful bout with the Big “C” proved the value of regular medical examinations and the benefit of early cancer detection.

“Surgery practically rids the patient of the cancer which is why I elected to go for one immediately,” Puno explained. “Subsequent treatments are meant to ensure that the possibility of recurrence is eliminated or, at least, diminished,” she added.

“I am fortunate to have discovered the cancer early and to benefit from available medical intervention,” Puno said. “Had it not been discovered early, the effectiveness of cancer treatments would have been significantly reduced,” she explained.

Puno explained that the occurrence of breast cancer are triggered by various causes.

“Unfortunately, the primary risk factor is just that – being a woman,” she said. Other risk factors include obesity, lack of physical exercise, diet choices and lifestyle.

“Medical experts estimate that about 10 percent of the cases of breast cancer in women are due to genes,” Puno said. “In other words, it is hereditary which was what happened in my case,” Puno pointed out.

“My bout with cancer was due to what are called ‘fixed risk factors’, or those over which an individual can do nothing about," she said. The other set of risk factors are “modifiable”, which means their effect can be reduced by changing certain things like diet and lifestyle.

“There were earlier concerns that work pressure may have triggered the development of cancer in me,” Puno recalled. The FDA head had said she had just been through a “tough year”, having laid down major reforms in the agency she heads.

The pharmacy board examinations topnotcher related that she had just overhauled many of the crucial public service systems and processes in the FDA.

Among these were the reduction of the time required to process applications, particularly for certificates of product registration (CPR). Puno also instituted a centralized system for receiving and distributing documents within the organization, as well as a process for releasing them. She explained that this was necessary to ensure that the FDA is “liberated from undue influence and pressure from brokers and fixers”.

Puno also directed massive operations against manufacturers and retailers of fake, counterfeit and unregistered drugs and wellness products since these exposed the public to serious health risks. The operations netted close to P80 Million in confiscated goods within a one-year period.

“While these were really high-pressure tasks, my doctors said they had nothing or little to do with the onset of breast cancer on my part,” Puno clarified. “The vulnerability of my situation was due more to the fact that the risk runs in our family,” she said.

Women diagnosed with breast cancer have choices as to their preferred surgical intervention, Puno said. 

“At the end of the day, this requires a serious discussion between patient and doctor with the patient making the final decision based on clear options.

“Modern medicine has expanded the range of options beyond chemotherapy and radiation therapy for the post-surgery stage,” Puno explained. Do not also discount the importance of getting a second medical opinion, she advised.

CDRR Officers of the Day for May 21-25, 2018

The Center for Drug Regulation and Research (CDRR) will be having the pre-strategic planning on 21-25 May 2108. In line with this, there will be no officers on duty for the said dates at the FDA Action Center (FDAC).

Given this, we advise our clients to kindly send all queries and concerns via e-mail to the following e-mail addresses, and we will respond accordingly;

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
  • This email address is being protected from spambots. You need JavaScript enabled to view it.

Thank you for the usual support.

For your information and guidance

Share Us on

Submit to FacebookSubmit to Google PlusSubmit to Twitter